Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADDERALL 12.5 vs AEROLATE III
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Adderall 12.5 is a combination of dextroamphetamine and amphetamine. It increases the levels of dopamine and norepinephrine in the central nervous system by inhibiting their reuptake and promoting their release from presynaptic neurons.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Attention deficit hyperactivity disorder (ADHD),Narcolepsy (off-label)
Treatment and prophylaxis of bronchospasm associated with asthma, chronic bronchitis, and emphysema,Off-label: Apnea of prematurity (oral/IV theophylline)
5-60 mg orally once or twice daily; immediate-release: initial 5 mg once or twice daily, increase by 5 mg weekly; extended-release: initial 20 mg once daily in the morning, increase by 10 mg weekly.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
The terminal elimination half-life of d-amphetamine is approximately 10–13 hours in adults (range 9–14 h) and 6–8 hours in children. Clinical context: Typically allows twice-daily dosing; extended-release formulations provide 8–12 hours of effect.
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Amphetamine and dextroamphetamine are extensively metabolized in the liver via CYP2D6 and other pathways. The primary metabolites are 4-hydroxyamphetamine and 4-hydroxynorephedrine.
Primarily hepatic via cytochrome P450 1A2 (CYP1A2); also CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics.
Approximately 30% of the dose is excreted unchanged in urine; the remainder is metabolized primarily via deamination and oxidation. Renal elimination of unchanged amphetamine is p H-dependent: acidic urine increases elimination, alkaline urine decreases it. Fecal excretion accounts for <5%.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Approximately 15–20% bound to plasma proteins, primarily albumin.
92-96%, primarily to albumin and alpha-1-acid glycoprotein
Mean volume of distribution is 3.5–4.6 L/kg, indicating extensive tissue distribution. Clinical meaning: Large Vd reflects sequestration in tissues (including brain), contributing to prolonged presence.
Vd 1.5-2.0 L/kg, indicating extensive tissue distribution
Oral bioavailability is highly variable, ranging from 75–100% for immediate-release tablets; food does not significantly affect overall absorption but may delay time to peak concentration. Extended-release capsules have bioavailability approximately 96% relative to immediate-release.
Oral: 40-50%; Inhalation: 20-30%
GFR 15-29 m L/min: reduce dose to 50% of usual; GFR <15 m L/min: use 50% of usual dose; hemodialysis: not removed, avoid use.
No adjustment needed for GFR >30 m L/min. For GFR 10-30 m L/min: use 50% of usual dose. For GFR <10 m L/min: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: use 50% of usual dose; Child-Pugh C: avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Immediate-release: 3-5 years: initial 2.5 mg once daily, increase by 2.5 mg weekly up to 40 mg/day; 6+ years: initial 5 mg once or twice daily, increase by 5 mg weekly up to 40 mg/day. Extended-release: 6-12 years: initial 10 mg once daily, increase by 10 mg weekly up to 30 mg/day; 13-17 years: initial 10 mg once daily, increase by 10 mg weekly up to 40 mg/day.
Children 2-11 years: 1 inhalation (100 mcg) twice daily via metered-dose inhaler. Children 12 years and older: same as adult.
Start at lowest dose (5 mg immediate-release or 10 mg extended-release) and titrate slowly due to increased risk of adverse cardiovascular and CNS effects; monitor for hypertension, tachycardia, and agitation.
No specific dose adjustment but monitor for increased systemic effects; start at lowest effective dose.
Adderall has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular adverse events.
No FDA black box warning.
Risk of abuse and dependence,Serious cardiovascular events including sudden death, stroke, and myocardial infarction,Blood pressure and heart rate increases,Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, or aggression,Seizures in patients with seizure disorders,Visual disturbances,Growth suppression in children,Peripheral vasculopathy including Raynaud's phenomenon,Serotonin syndrome risk when used with serotonergic drugs
Monitor serum theophylline concentrations due to narrow therapeutic index; risk of toxicity at levels >20 mcg/m L; use caution in patients with cardiac disease, hepatic impairment, or seizures; may exacerbate arrhythmias; drug interactions with cimetidine, fluoroquinolones, macrolides, allopurinol, oral contraceptives, smoking, and others.
Known hypersensitivity to amphetamine products or other sympathomimetic amines,Concomitant use with MAOIs or within 14 days of MAOI therapy,Glaucoma,Hyperthyroidism,Agitated states,History of drug abuse,Cardiovascular disease including moderate to severe hypertension, advanced arteriosclerosis, symptomatic cardiovascular disease, or tachyarrhythmias
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (e.g., ventricular tachycardia); recent myocardial infarction; uncontrolled seizure disorders.
Avoid acidic foods and beverages (e.g., citrus fruits, soda) within 1 hour of administration as they may decrease absorption. High-fat meals may delay absorption of extended-release formulations. Avoid caffeine and other stimulants. Grapefruit juice may increase amphetamine levels.
Avoid significant intake of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase CNS stimulation and risk of toxicity. Charcoal-broiled foods and a high-protein diet may increase clearance. Maintain consistent dietary patterns; avoid extremes of protein/carbohydrate intake.
First trimester: Increased risk of congenital malformations, particularly cardiovascular defects (e.g., septal defects) and oral clefts based on amphetamine exposure. Second and third trimesters: risk of preterm delivery, low birth weight, and neonatal withdrawal syndrome (irritability, feeding difficulties, respiratory distress). Premature delivery and growth restriction have been reported.
AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal heart rate, jitteriness, and risk of neonatal apnea with high maternal serum concentrations (>15 mcg/m L). Avoid near term due to prolonged neonatal half-life.
Contraindicated due to potential for infant toxicity. M/P ratio not established; amphetamine is excreted into breast milk in small amounts but may accumulate in breastfeeding infants. Adverse effects include irritability, poor feeding, and decreased weight gain.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach 50% of maternal levels; risk of irritability and sleep disturbances in nursing infants. Use with caution and monitor infant for signs of toxicity.
Pharmacokinetics altered: increased hepatic metabolism and renal clearance in pregnancy may reduce amphetamine exposure; however, safety data do not support dose adjustment. Use lowest effective dose only if necessary; consider alternative non-amphetamine therapies.
Pregnancy may increase theophylline clearance due to enhanced hepatic metabolism and increased renal blood flow. Dose adjustments are often required: monitor serum levels regularly and adjust dose to maintain therapeutic levels. Typically, dose may need to be increased by 20-50% in second and third trimesters.
ADDERALL 12.5 mg is a fixed-dose combination of amphetamine and dextroamphetamine. Monitor for cardiovascular events, especially in patients with pre-existing heart conditions. Onset of action occurs within 30-60 minutes; duration of action is approximately 4-6 hours. Avoid late afternoon doses to prevent insomnia. Use with caution in patients with a history of drug abuse. May cause growth suppression in children; monitor height and weight. Do not crush or chew extended-release capsules.
AEROLATE III (theophylline) is a bronchodilator with a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L). Caffeine and smoking increase clearance; hepatic impairment, heart failure, and certain drugs (e.g., cimetidine, fluoroquinolones) decrease clearance. Avoid use in patients with active peptic ulcer or seizure disorders. Titrate dose slowly to minimize nausea, vomiting, and arrhythmias.
Take exactly as prescribed; do not increase dose without consulting your doctor.,Swallow the capsule whole; do not chew, crush, or open it.,Avoid alcohol while taking this medication.,Do not drive or operate machinery until you know how this medication affects you.,Report any chest pain, shortness of breath, or fainting to your doctor immediately.,Store at room temperature away from moisture and heat.
Take this medication exactly as prescribed; do not crush or chew extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects like jitteriness and insomnia.,Inform your doctor if you experience nausea, vomiting, rapid heartbeat, or seizures.,Do not stop taking this medication abruptly; taper under medical supervision.,Keep all appointments for blood tests to monitor theophylline levels.,Avoid smoking or using nicotine products, as they affect how the medication works.,Carry a list of all medications you take, as many can interact with theophylline.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADDERALL 12.5 vs AEROLATE III, answered by our medical review team.
ADDERALL 12.5 is a CNS Stimulant that works by Adderall 12.5 is a combination of dextroamphetamine and amphetamine. It increases the levels of dopamine and norepinephrine in the central nervous system by inhibiting their reuptake and promoting their release from presynaptic neurons.. AEROLATE III is a Bronchodilator that works by AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADDERALL 12.5 and AEROLATE III depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADDERALL 12.5 is: 5-60 mg orally once or twice daily; immediate-release: initial 5 mg once or twice daily, increase by 5 mg weekly; extended-release: initial 20 mg once daily in the morning, increase by 10 mg weekly.. The standard adult dose of AEROLATE III is: Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADDERALL 12.5 and AEROLATE III in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADDERALL 12.5 is classified as Category C. First trimester: Increased risk of congenital malformations, particularly cardiovascular defects (e.g., septal defects) and oral clefts based on amphetamine exposure. Second and th. AEROLATE III is classified as Category C. AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.